Crystal form of compound for inhibiting the activity of CDK4/6 and use thereof
US12043622B2 · kind B2 · utility
0Cited by
1References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 21, 2019 |
| Grant date | Jul 23, 2024 |
| Priority date | — |
| Expiry date | Jun 28, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to a salt form of (R)—N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(6-fluoro-1-methyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)pyrimidin-2-amine (compound I) as shown in structural formula (I) or a crystal form thereof, and also relates to a method for preparing the salt form of compound I and/or the crystal form thereof, a pharmaceutical composition containing the salt form and/or the crystal form, and the use of same in the preparation of drugs for treating diseases, illnesses or conditions, or a method for treating diseases, illnesses or conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.